Elisa Garbayo
Overview
Explore the profile of Elisa Garbayo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
615
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blanco-Prieto M, Garbayo E
Adv Drug Deliv Rev
. 2024 Oct;
216:115471.
PMID: 39481484
No abstract available.
2.
Garbayo E, El Moukhtari S, Rodriguez-Nogales C, Agirre X, Rodriguez-Madoz J, Rodriguez-Marquez P, et al.
Adv Drug Deliv Rev
. 2024 Sep;
214:115448.
PMID: 39303823
Hematological cancers encompass a diverse group of malignancies affecting the blood, bone marrow, lymph nodes, and spleen. These disorders present unique challenges due to their complex etiology and varied clinical...
3.
Gil-Cabrerizo P, Simon-Yarza T, Garbayo E, Blanco-Prieto M
Adv Drug Deliv Rev
. 2024 Apr;
208:115302.
PMID: 38574952
Cardiovascular diseases (CVDs) stand as the leading cause of death worldwide, posing a significant global health challenge. Consequently, the development of innovative therapeutic strategies to enhance CVDs treatment is imperative....
4.
El Moukhtari S, Garbayo E, Amundarain A, Pascual-Gil S, Carrasco-Leon A, Prosper F, et al.
J Control Release
. 2023 Aug;
361:130-146.
PMID: 37532145
RNA-based therapies, and siRNAs in particular, have attractive therapeutic potential for cancer treatment due to their ability to silence genes that are imperative for tumor progression. To be effective and...
5.
Gil-Cabrerizo P, Scacchetti I, Garbayo E, Blanco-Prieto M
Eur J Pharm Sci
. 2023 Apr;
185:106439.
PMID: 37003408
Myocardial infarction is one of the major causes of morbidity and mortality worldwide. Current treatments can relieve the symptoms of myocardial ischemia but cannot repair the necrotic myocardial tissue. Novel...
6.
Gil-Cabrerizo P, Saludas L, Prosper F, Abizanda G, de Anleo M, Ruiz-Villalba A, et al.
Int J Pharm
. 2022 Nov;
629:122356.
PMID: 36332831
Extracellular vesicles (EVs) are nanosized particles with attractive therapeutic potential for cardiac repair. However, low retention and stability after systemic administration limit their clinical translation. As an alternative, the combination...
7.
Torres-Ortega P, Del Campo-Montoya R, Plano D, Paredes J, Aldazabal J, Luquin M, et al.
Biomacromolecules
. 2022 Oct;
23(11):4629-4644.
PMID: 36288499
The co-administration of glial cell line-derived neurotrophic factor (GDNF) and mesenchymal stem cells (MSCs) in hydrogels (HGs) has emerged as a powerful strategy to enhance the efficient integration of transplanted...
8.
Del Campo-Montoya R, Luquin M, Puerta E, Garbayo E, Blanco-Prieto M
Expert Opin Drug Deliv
. 2022 Oct;
19(11):1521-1537.
PMID: 36240170
Introduction: Parkinson's disease is the second most common neurodegenerative disease. Currently, there are no curative therapies, with only symptomatic treatment available. One of the principal reasons for the lack of...
9.
Special issue on the latest advances in regenerative medicine and cancer using drug delivery systems
Blanco-Prieto M, Garbayo E
Eur J Pharm Biopharm
. 2022 Jun;
177:89-90.
PMID: 35750107
No abstract available.
10.
El Moukhtari S, Garbayo E, Fernandez-Teijeiro A, Rodriguez-Nogales C, Couvreur P, Blanco-Prieto M
J Control Release
. 2022 Jun;
348:553-571.
PMID: 35705114
Embryonal tumors of the nervous system are neoplasms predominantly affecting the pediatric population. Among the most common and aggressive ones are neuroblastoma (NB) and medulloblastoma (MB). NB is a sympathetic...